Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Other Working Capital Changes (2016 - 2025)

Sunshine Biopharma (SBFM) has disclosed Other Working Capital Changes for 13 consecutive years, with -$36168.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Working Capital Changes rose 56.81% year-over-year to -$36168.0, compared with a TTM value of $166842.0 through Sep 2025, up 841.07%, and an annual FY2024 reading of $207167.0, up 879.84% over the prior year.
  • Other Working Capital Changes was -$36168.0 for Q3 2025 at Sunshine Biopharma, up from -$115617.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $568981.0 in Q1 2024 and bottomed at -$736637.0 in Q2 2024.
  • Average Other Working Capital Changes over 5 years is -$6284.5, with a median of -$21172.0 recorded in 2022.
  • The sharpest move saw Other Working Capital Changes surged 1148.48% in 2021, then tumbled 1860.45% in 2022.
  • Year by year, Other Working Capital Changes stood at $4579.0 in 2021, then crashed by 1860.45% to -$80611.0 in 2022, then soared by 433.85% to $269120.0 in 2023, then soared by 70.39% to $458558.0 in 2024, then plummeted by 107.89% to -$36168.0 in 2025.
  • Business Quant data shows Other Working Capital Changes for SBFM at -$36168.0 in Q3 2025, -$115617.0 in Q2 2025, and -$139931.0 in Q1 2025.